Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 14 of 15 for:    "Guillain-Barre syndrome"

Perception and Multisensory Integration in Neurological Patients Using fMRI

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified September 2011 by Hadassah Medical Organization
Sponsor:
Information provided by (Responsible Party):
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01469858
First received: November 1, 2011
Last updated: November 8, 2011
Last verified: September 2011
  Purpose

The main objective of the study is to explore and map brain areas involved in sensory perception and multisensory integration in patients with central or peripheral neurological damage. The investigators hypothesize for example, that a change (compare to healthy subjects) in the perceptual maps and body representation could be detected and characterize in patients suffering from impairments of peripheral nerve conduction.


Condition Intervention
Acute Inflammatory Demyelinating Polyradiculoneuropathy
Myasthenia Gravis
Stroke
Anosognosia
Asomatognosia
Device: Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Perception and Multisensory Integration in Neurological Patients Using fMRI

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • assessing hemodynamic responses by measurement of the Blood-oxygen-level dependence(BOLD)signal [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Distinct maps of sensory and multisensory representations related to certain disorders will be assed by measurement of the Blood-oxygen-level dependence(BOLD)signal.


Estimated Enrollment: 30
Study Start Date: November 2011
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: study group
fMRI
Device: Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla
functional magnetic resonance imaging

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • diagnosis of the investigated neuronal disease

Exclusion Criteria:

  • contraindication for MRI scan
  • pregnancy
  • refusal to participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01469858

Contacts
Contact: Shahar Arzi, MD PhD 97226777741 shahar.arzy@gmail.com

Locations
Israel
Hadassah Medical Organization Not yet recruiting
Jerusalem, Israel
Contact: Arik Tzukert, DMD    00 972 2 6776095    arik@hadassah.org.il   
Contact: Hadas Lemberg, PhD    00 972 2 6777572    lhadas@hadassah.org.il   
Principal Investigator: Shahar Arzy, MD PhD         
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

Publications:
Responsible Party: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT01469858     History of Changes
Other Study ID Numbers: 044811HMO
Study First Received: November 1, 2011
Last Updated: November 8, 2011
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Guillain-Barre Syndrome
Myasthenia Gravis
Polyradiculoneuropathy
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Neuromuscular Diseases
Neuromuscular Junction Diseases
Peripheral Nervous System Diseases
Polyneuropathies

ClinicalTrials.gov processed this record on November 19, 2014